A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of Washington
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
BeOne Medicines
Gilead Sciences
Novartis
H. Lee Moffitt Cancer Center and Research Institute
University of Washington
University of Washington
Thomas Jefferson University
Novartis
National Cancer Institute (NCI)
Insel Gruppe AG, University Hospital Bern
University of Washington
Masonic Cancer Center, University of Minnesota
University of Maryland, Baltimore
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
PrECOG, LLC.
Incyte Corporation
Fred Hutchinson Cancer Center
Columbia University
Janssen Research & Development, LLC
Masonic Cancer Center, University of Minnesota
MEI Pharma, Inc.
AstraZeneca
Amgen
Fondazione Italiana Linfomi - ETS
Oppilan Pharma Ltd
BeiGene
Incyte Corporation
M.D. Anderson Cancer Center
Academic and Community Cancer Research United
Novartis
Duke University
Ipsen
University of Colorado, Denver
City of Hope Medical Center
City of Hope Medical Center
Mayo Clinic
BioAegis Therapeutics Inc.
University of Nebraska
Vanderbilt-Ingram Cancer Center
ADC Therapeutics S.A.
University of Nebraska
University of Nebraska
TG Therapeutics, Inc.